



November 12th, 2021

Santen to Present Latest Data on Omidenepag Isopropyl
at AAO 2021

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka, hereinafter “Santen”) announced today that some publications including EP2 receptor agonist, omidenepag isopropyl, will be presented at the American Academy of Ophthalmology’s annual meeting (AAO 2021; <https://www.aao.org/annual-meeting>) from November 12th to 15th, 2021.

Omidenepag isopropyl has been sold in Japan and Asia since 2018 as *EYBELIS Ophthalmic Solution 0.002%*, a treatment for glaucoma and ocular hypertension. Santen submitted the New Drug Application in the United States. (PDUFA¹ date: November 19th, 2021, Development code: STN1011700). At this conference, some presentations including the outcome of the pivotal studies submitted in U.S. will be conducted.

Presentation topics

Session #	Title
PA041	Omidenepag Isopropyl 0.002% vs. Latanoprost 0.005% in Open-angle Glaucoma/Ocular Hypertension: The Phase 3 PEONY Trial
PO215	Omidenepag Isopropyl vs. Timolol Maleate for Open-angle Glaucoma/Ocular Hypertension: The Phase 3 Spectrum 4 Trial
PO241	Efficacy and Safety of DE-127 vs. Placebo in Mild or Moderate Myopia: The APPLE Study
PO007	Safety and Effectiveness of MicroShunt ² Implantation versus Trabeculectomy: 2-year Results from a Randomized, Multicenter Study

For abstracts, please see the following link; <https://registration.experientevent.com/showaao211/flow/Attendee#!/registrant/ShowItems/>

1 Prescription Drug User Fee Act

2 Glaukos Corporation (San Clemente, CA, U.S.) is responsible for developing and selling products in the Americas, Australia, and New Zealand (press release on May 19, 2021; <https://www.santen.com/en/news/20210519-1.pdf>).

Contact:

Investor Relations Group

Santen Pharmaceutical Co., Ltd.

E-mail: ir@santen.com